TCF7L2 genetic variation augments incretin resistance and influences response to a sulfonylurea and metformin: The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH)

Diabetes Care

Volumn 41, Issue 3, 2018, Pages 554-561

  Srinivasan, Shylaja ^a,b   Kaur, Varinderpal ^a   Chamarthi, Bindu ^b,c   Littleton, Katherine R ^a   Chen, Ling ^a   Manning, Alisa K ^a,d   Merino, Jordi ^a   Thomas, Melissa K ^e   Hudson, Margo ^b,c   Goldfine, Allison ^b,f   Florez, Jose C ^a,b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIPIZIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; METFORMIN; TRANSCRIPTION FACTOR 7 LIKE 2; SULFONYLUREA DERIVATIVE; TCF7L2 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENETIC VARIABILITY; GENOTYPE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HOMOZYGOTE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MIDDLE AGED; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; SINGLE DRUG DOSE; TCF7L2 GENE; AGED; BLOOD; GENETICS; GENOTYPING TECHNIQUE; GLUCOSE TOLERANCE TEST; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ALLELES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPING TECHNIQUES; GLIPIZIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; INCRETINS; MALE; METFORMIN; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SULFONYLUREA COMPOUNDS; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN;

EID: 85042445866     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-1386     Document Type: Article

References (42)

1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
2. Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non-insulindependent diabetes mellitus. Arch Intern Med 1997;157:836-848.
3. Mahajan A, Go MJ, Zhang W, et al.; DIAbetes Genetics ReplicationAndMeta-Analysis (DIAGRAM) Consortium; AsianGenetic EpidemiologyNetwork Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium;Mexican American Type 2 Diabetes (MAT2D) Consortium; Type 2 Diabetes Genetic Exploration by Nex-generation sequencing in muylti-Ethnic Samples (T2D-GENES)Consortium. Genome-wide transancestry meta-Analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet 2014;46:234-244.
4. Cho YS, Chen CH, Hu C, et al.; DIAGRAM Consortium; MuTHER Consortium. Meta-Analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. Nat Genet 2011;44:67-72.
5. Ma RC, Hu C, Tam CH, et al.; DIAGRAM Consortium; MuTHER Consortium. Genome-wide association study in a Chinese population identifies a susceptibility locus for type 2 diabetes at 7q32 near PAX4.Diabetologia 2013;56:1291-1305.
6. Voight BF, Scott LJ, Steinthorsdottir V, et al.; MAGIC investigators; GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010;42:579-589.
7. Morris AP, Voight BF, Teslovich TM, et al.; Wellcome Trust Case Control Consortium; Meta- Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation ofANthropometric Traits (GIANT) Consortium; Asian Genetic Epidemiology Network-Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; DIAbetes Genetics Replication and Meta-Analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012;44:981-990.
8. Steinthorsdottir V, Thorleifsson G, Sulem P, et al. Identification of low-frequency and rare sequence variants associated with elevated or reduced riskof type 2diabetes.NatGenet 2014;46:294-298.
9. Zhou K, Donnelly L, Yang J, et al.; Wellcome Trust Case Control Consortium 2. Heritability of variation in glycaemic response to metformin: A genome-wide complex trait analysis. Lancet Diabetes Endocrinol 2014;2:481-487.
10. Zhou K, Bellenguez C, Spencer CC, et al.; GoDARTS and UKPDS Diabetes Pharmacogenetics StudyGroup; Wellcome Trust Case Control Consortium 2; MAGIC investigators. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 2011; 43:117-120.
11. Zhou K, Yee SW, Seiser EL, et al.; MetGen Investigators; DPP Investigators; ACCORD Investigators. Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet 2016;48:1055-1059.
12. BeckerML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH. Cytochrome P450 2C9 ∗2 and ∗3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 2008;83:288-292.
13. Florez JC. Pharmacogenetic perturbations in humans as a tool to generate mechanistic insight. Diabetes 2013;62:3019-3021.
14. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-323.
15. Helgason A, Pá lsson S, Thorleifsson G, et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution.NatGenet 2007;39:218-225.
16. Florez JC, Jablonski KA, Bayley N, et al.; Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006;355:241-250.
17. Saxena R, Gianniny L, BurttNP, et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006;55:2890-2895.
18. Scott LJ, Bonnycastle LL, Willer CJ, et al. Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 2006;55:2649-2653.
19. Dabelea D, Dolan LM, D'Agostino R Jr, et al. Association testing of TCF7L2 polymorphisms with type 2 diabetes inmulti-ethnic youth. Diabetologia 2011;54:535-539.
20. Jin T, Liu L. The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus. Mol Endocrinol 2008;22:2383-2392.
21. Walford GA, Colomo N, Todd JN, et al. The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH):design of a pharmacogenetic resource for type 2 diabetes. PLoS One 2015;10:e0121553.
22. Centers for Disease Control and Prevention [Internet], 2017. About adult BMI. Available from https://www.cdc.gov/healthyweight/assessing/bmi/adult-bmi/index.html. Accessed 1February 2017.
23. Accelerating Medicines Partnership (AMP). Type 2 diabetes knowledge portal [Internet], 2017. Available from http://www.type2diabetesgenetics.org/gene/geneInfo/TCF7L2. Accessed 1 February 2017.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations inman. Diabetologia 1985;28:412-419.
25. Stumvoll M, Van Haeften T, Fritsche A, Gerich J. Oral glucose tolerance test indexes for insulin sensitivity and secretion based on various availabilities of sampling times. Diabetes Care 2001;24:796-797.
26. Dupuis J, Langenberg C, Prokopenko I, et al.; DIAGRAM Consortium; GIANT Consortium; Global BPgen Consortium; Anders Hamsten on behalf of Procardis Consortium; MAGIC investigators. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42:105-116.
27. Bailey KA, Savic D, Zielinski M, et al. Evidence of non-pancreatic beta cell-dependent roles of Tcf7l2 in the regulation of glucose metabolism in mice. Hum Mol Genet 2015;24:1646-1654.
28. Boj SF, van Es JH, Huch M, et al. Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell 2012;151:1595-1607.
29. Shah M, Varghese RT, Miles JM, et al. TCF7L2 genotype and a-cell function in humans without diabetes. Diabetes 2016;65:371-380.
30. Schafer SA, Tschritter O, Machicao F, et al. Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007;50:2443-2450.
31. Villareal DT, Robertson H, BellGI, et al. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010;59: 479-485.
32. Pilgaard K, Jensen CB, Schou JH, et al. The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men. Diabetologia 2009;52:1298- 1307.
33. Pearson ER, Flechtner I, Njølstad PR, et al.; Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467-477.
34. Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: A GoDARTs study. Diabetes 2007;56:2178-2182.
35. Heni M, Ketterer C, Thamer C, et al. Glycemia determines the effect of type 2 diabetes risk genes on insulin secretion. Diabetes 2010;59: 3247-3252.
36. Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 2008;283:8723-8735.
37. Shu Y, Brown C, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008;83:273-280.
38. Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest 2007;117:2155-2163.
39. Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 2005;280: 1457-1464.
40. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999;20:876-913.
41. Færch K, Pilgaard K, Knop FK, et al. Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele. Diabetes Obes Metab 2013;15: 91-95.
42. Zimdahl H, Ittrich C, Graefe-Mody U, et al. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia 2014;57:1869- 1875.